*Read Disclaimer Sponsored Content | Unsubscribe
Hello!
New Alert: Immix Biopharma, Inc. (NASDAQ: IMMX)
IMMX is our brand new NASDAQ alert.
In October, IMMX rallied +102% from 2.00 to a high of 4.05.
Since this rally, IMMX has been consolidating above its 20 day moving average of 3.20.
This is a typical move after such a massive rally.
If it can hold above this level then it could be positioning for another rally higher.
IMMX is the "global leader in relapsed/refractory AL Amyloidosis".
Each of our bodies has an immune system that recognizes and eliminates disease on a daily basis.
When AL Amyloidosis emerges from our own body, however, the diseased cells are able to evade the immune system.
"AL Amyloidosis is a devastating disease where the immune system, that's supposed to protect, instead produces toxic light chains, clogging up the heart, kidney and liver, causing organ failure and death."
Sadly, "only one 4-drug combination exists for newly diagnosed patients only".
However, "once relapse hits, there's nothing FDA approved".
"Doctors often resort to reusing older drugs, despite their limited efficacy."
IMMX found a breakthrough to change that hopeless sentence.
The company's mission is simple – "Create medicines that work without destroying the patient."
IMMX re-engineers the immune system to fight again.
IMMX's "lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 with a "digital filter" that filters out non-specific activation."
"NXC-201 CAR-T therapy, or chimeric antigen receptor T-cell therapy, is a type of immunotherapy that uses the patient's own immune cells, modified with ImmixBio proprietary technology, to create NXC-201, which is then introduced into the patient's body."
"Then the patient's modified NXC-201 CAR-T cells are able to recognize and eliminate diseased cells, with up to a 92% rate of disease reduction (overall response rate) in the case of relapsed/refractory AL Amyloidosis."
In other words:
- "NXC-201 teaches the immune system to recognize and eliminate the source of the toxic light chains."
Despite impressive research and development progress in CAR-T cell therapies, "today 95% of U.S. medical centers are unable to dose CAR-T cell therapies due to neurotoxicity, and only a narrow band of patients in specific indications are able to benefit from CAR-Ts".
IMMX is "aiming to become the first company to overcome the greatest obstacle to CAR-T adoption: neurotoxicity".
By overcoming neurotoxicity, IMMX aims to "expand into select other serious diseases that were not possible in the past (starting with AL Amyloidosis), and places not possible in the past (the 95% of U.S. medical centers today that are unable to dose CAR-T therapies)".
"NXC-201 is being evaluated in the U.S. multi-center study for relapsed/refractory AL Amyloidosis NEXICART-2 (NCT06097832), with a registrational design."
Importantly:
- "NXC-201 has been awarded Regenerative Medicine Advanced Therapy (RMAT) by the US FDA and Orphan Drug Designation (ODD) by FDA and in the EU by the EMA."
Unfortunately, the "number of patients in the U.S. with relapsed/refractory AL Amyloidosis is estimated to be growing at 12% per year according to Staron, et al Blood Cancer Journal, to approximately 37,270 patients in 2025".
The Amyloidosis market was "$3.6 billion in 2017, and is expected to reach $6 billion in 2025, according to Grand View Research".
IMMX has announced multiple accomplishments over the past few months.
In August, the company announced:
"Immix Biopharma Announces Other Serious Diseases Strategy"
Here are the comments from this press release:
"While we are singularly focused on completing NEXICART-2 in relapsed/refractory AL Amyloidosis for BLA submission, promising NXC-201 clinical results could offer extraordinary one-and-done solutions in a number of other serious diseases. We plan to explore licensing-out these OSD programs through external partnerships," said Ilya Rachman, M.D., Ph.D., Chief Executive Officer of Immix Biopharma. Gabriel Morris, Chief Financial Officer of Immix Biopharma, added, "We believe partnerships could fuel our path to NEXICART-2 BLA submission for FDA approval and future development programs."
In addition, in September, the company announced:
"Immix Biopharma Announces Strategic Investment by Houston based Goose Capital, led by founding member Dr. Nancy T. Chang"
Here are some of the comments from this press release:
"Immix's mission of curing the incurable resonates with Goose's goal of investing in breakthrough technologies and innovative founders to forge the future of human medicine," said Anthony George, President of Goose Capital. Ashok Rao, Board Member of Goose Capital, added, "After a deep evaluation of the technology, team, and market that Immix is pursuing, we are pleased to support, and anticipate exciting progress to-come."
"We are thrilled that Dr. Chang and Goose recognize the opportunity for commercialization of NXC-201 in relapsed/refractory AL Amyloidosis, other serious diseases, and beyond," said Ilya Rachman, M.D., Ph.D., Chief Executive Officer of Immix Biopharma. Gabriel Morris, Chief Financial Officer of Immix Biopharma, added, "Goose and Dr. Chang bring unparalleled experience to the Immix team. Dr. Chang led XOLAIR® from invention through FDA approval and commercialization, further enabling our goal to deliver widely accessible cures, as patients are waiting."
As the company further noted in:
"Nancy T. Chang, Proven Biotechnology Leader, Joins Immix Biopharma Board of Directors"
"At Tanox, Dr. Chang and her team invented and developed FDA-approved XOLAIR® (omalizumab) for severe asthma, TROGARZO® (ibalizumab-uiyk) for HIV, and EBGLYSS® (lebrikizumab-lbkz) for dermatitis, collectively generating drug sales exceeding 5 billion dollars so far."
Plus:
- "Tanox, Inc. was acquired by Genentech/Roche for $919 million."
- "EBGLYSS® is commercialized by Eli Lilly and Co."
In addition, in September, the company announced:
"Immix Biopharma Announces 50% Enrollment Milestone Surpassed in its ongoing relapsed/refractory AL Amyloidosis Clinical Trial, NEXICART-2"
Here are some of the company's comments from this press release:
"With excitement generated by our clinical results presented at ASCO, surpassing 50% enrollment in NEXICART-2 demonstrates the growing interest among relapsed/refractory AL Amyloidosis clinicians and patients, where no drugs are FDA approved today," said Ilya Rachman, M.D., Ph.D., Chief Executive Officer of Immix Biopharma. Gabriel Morris, Chief Financial Officer of Immix Biopharma, added, "Growing excitement accelerates NEXICART-2 BLA submission for FDA approval, and supports future commercial awareness."
In addition, IMMX will be participating at multiple conferences over the coming weeks:
"Immix Biopharma to Present at the Stifel 2025 Healthcare Conference"
- "announced that it will present and host institutional investor meetings at the Stifel 2025 Healthcare Conference being held on November 11-13, 2025 at the Lotte New York Palace Hotel in New York, NY."
"Immix Biopharma to Present at the 37th Annual Piper Sandler Healthcare Conference"
- "announced that it will present and host institutional investor meetings at the 37th Annual Piper Sandler Healthcare Conference being held on December 2-4, 2025 at the Lotte New York Palace Hotel in New York, NY."
"Immix Biopharma to Present Abstract at the upcoming ASH 2025 Annual Meeting"
- "announced that it will present a NXC-201 abstract at the upcoming American Society of Hematology (ASH) 67th Annual Meeting and Exposition to be held December 6-9, 2025, in Orlando, Florida."
"Immix Biopharma to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference"
- "announced that it will present and host institutional investor meetings at the Guggenheim 2nd Annual Healthcare Innovation Conference being held November 10-12, 2025 in Boston, MA."
- "Management will participate in a Fireside Chat on Tuesday, November 11, 2025 at 12:30pm Eastern Time."
"Immix Biopharma's NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025"
- "announced that Phase 1/2 interim results from its U.S. NXC-201 NEXICART-2 trial in relapsed/refractory AL Amyloidosis has been selected for oral presentation at the upcoming American Society of Hematology 2025 Annual Meeting (ASH 2025) being held in Orlando, Florida, December 6–9, 2025."
IMMX could be positioned for another breakout opportunity.
Make sure to do your own due diligence.
Sources: Presentation, PR1, PR2, PR3, PR4, PR5, PR6, PR7, PR8, PR9, Website, Chart
Happy Trading!
UltimateStockAlerts Team
Note: We encourage all traders and investors to develop personal trading rules that you can follow and that work for you. Always protect your downside and note that we alert extremely volatile short-term opportunities. Before investing in securities, you should always consult with your financial, tax and legal advisor and never invest money you cannot afford to lose.
